VP External Research
Michael Saunders has been discovering novel drugs and selecting therapeutic targets for 25 years. At argenx for more than 6 years, he is currently responsible for External Research and the Innovative Access Program. At argenx, he has contributed to the discovery of four antibodies in clinical and preclinical development, for establishment and maintenance of academic collaborations and Alliance Management with Pharma partners (Shire, Bayer, Eli Lilly) and obtaining 4 Research Grants (>9M€).Michael Saunders holds at M.A. from Cambridge University (UK), a PhD in Biology from the University North Carolina (USA) and undertook postdoctoral training in the laboratory of Professor Pierre Chambon in Strasbourg (France). He also received general management training (EMBA) at ESSEC (France) and Mannheim Business School (Germany).
External Research and development